| dc.contributor.author | Gaikwad, Anil Bhanudas | |
| dc.date.accessioned | 2023-12-19T09:32:15Z | |
| dc.date.available | 2023-12-19T09:32:15Z | |
| dc.date.issued | 2018-09 | |
| dc.identifier.uri | https://academic.oup.com/cardiovascres/article/115/2/373/5090455?login=true | |
| dc.identifier.uri | http://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13452 | |
| dc.description.abstract | LCZ696, a first-generation dual angiotensin receptor-neprilysin inhibitor (ARNi), is effective in treating heart failure patients. However, the role of ARNis in treating diabetic cardiomyopathy is poorly understood. This study evaluates the efficacy of a novel combination of telmisartan [angiotensin receptor blocker (ARB)] and thiorphan [neprilysin inhibitor (NEPi)] in ameliorating diabetic cardiomyopathy while, at the same time, exploring the relevant underlying molecular mechanism(s). | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Oxford | en_US |
| dc.subject | Pharmacy | en_US |
| dc.subject | LCZ696, | en_US |
| dc.subject | Cardiomyopathy | en_US |
| dc.subject | Diabetic nephropathy | en_US |
| dc.title | Telmisartan and thiorphan combination treatment attenuates fibrosis and apoptosis in preventing diabetic cardiomyopathy | en_US |
| dc.type | Article | en_US |
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||